Oxford Immunotec Global PLC (OXFD) Stock Price Up 2.4%
Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) rose 2.4% during trading on Monday . The company traded as high as $8.34 and last traded at $8.23, with a volume of 54,596 shares changing hands. The stock had previously closed at $8.04.
OXFD has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, May 4th. BTIG Research reaffirmed a “buy” rating and set a $17.00 price objective on shares of Oxford Immunotec Global PLC in a research note on Monday, June 27th. Finally, Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Oxford Immunotec Global PLC in a research note on Sunday, June 26th.
The company’s 50 day moving average price is $8.78 and its 200-day moving average price is $9.77. The stock’s market capitalization is $185.27 million.
An institutional investor recently raised its position in Oxford Immunotec Global PLC stock. OppenheimerFunds Inc. raised its stake in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) by 0.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,068,967 shares of the company’s stock after buying an additional 5,440 shares during the period. OppenheimerFunds Inc. owned 4.74% of Oxford Immunotec Global PLC worth $12,293,000 at the end of the most recent reporting period.
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.